Drugs / Radiotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04866836 | Oct 2020 → Dec 2021 | cholangiocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radiotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04866836 ↗ |
| Modality | Monoclonal antibody | “PD-1 monoclonal antibody treatment” NCT04866836 ↗ |
| Route | Intravenous | “tislelizumab was given 200 mg, IVD, q3w” NCT04866836 ↗ |